Proto Axiom launches inaugural biotech pitch event
Proto Axiom, the Australian biotech incubator, has announced the launch of The Challenger Summit — a platform for researchers to showcase their innovative biotech solutions while competing for $250,000 in grant financing.
Proto Axiom is dedicated to nurturing and accelerating the growth of early-stage biotech ventures. By providing essential resources, mentorship and funding, the incubation firm aims to transform innovative ideas into successful biotech solutions that address global health challenges.
The Challenger Summit is designed to bring together the brightest minds from Australian universities, research institutes and public health systems. The funding available will help to accelerate research and drive the development of cutting-edge biotechnologies in Australia, while all presenting researchers will gain invaluable exposure and support from industry leaders.
The summit will:
- identify innovative science with commercial potential which advances the field of human health;
- support researchers affiliated with Australian universities and research institutes;
- include a simplified process that is quick and easy for applicants;
- simulate the process of investment by commercial funders, including detailed feedback and coaching, so that researchers are best equipped for future fundraising.
The winners of the $150,000 Challenger Prize and the $100,000 Open Prize will be announced at the inaugural Challenger Summit, to be held at the St Vincent’s Health Innovation Precinct Sydney in October 2024.
“We are excited to host The Challenger Summit and look forward to seeing the innovative ideas that will shape the future of biotechnology,” said Anthony Liveris, CEO of Proto Axiom.
“This event underscores our commitment to fostering a vibrant biotech ecosystem in Australia and supporting the next generation of researchers.”
Entries for The Challenger Summit are due by 12 July and finalists will be notified by mid-August. For more information and to apply for the summit, visit https://www.protoaxiom.com/applications/challenger.
Vaxxas to advance its microarray patches for COVID vaccination
Vaxxas will receive AU$3.2m from BARDA to accelerate work advancing its high-density microarray...
Global competition targets 'undruggable' cancer protein
A new global competition offering over US$500,000 in prizes aims to spur drug discovery...
SMi Systems appoints Dr Ankur Mutreja as Senior Advisor
Mutreja was previously Head of Global South Partnerships at CEPI, where he was responsible for...
